Excretion of cytosine arabinoside in saliva after its administration at high doses

Anti-Cancer Drugs

Volumn 17, Issue 5, 2006, Pages 597-598

  Mori, Takehiko ^a   Yamazaki, Rie ^a   Nakazato, Tomonori ^a   Aisa, Yoshinobu ^a   Enoki, Sawako ^b   Arai, Masaaki ^b   Ikeda, Yasuo ^a   Okamoto, Shinichiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SRL INC   (Japan)

Author keywords

Cytarabine; Cytosine arabinoside; High dose; Saliva

Indexed keywords

CYCLOSPORIN A; CYTARABINE; HYDROCORTISONE; METHOTREXATE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG INFUSION; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERSENSITIVITY REACTION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROPHYLAXIS; SALIVA; SAMPLING; STOMATITIS; TREATMENT DURATION;

EID: 33748136044     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200606000-00015     Document Type: Article

References (10)

1. Early AP, Preisler HD, Slocum H, Rustum YM. A pilot study of high-dose 1-β-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res 1982; 42:1587-1594.
2. Herzig R, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62:361-369.
3. Okamoto S, Takahashi S,Wakui M, Ishida A, Tanosaki R, Ikeda Y, et al. Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte-colony stimulating factor preceding allogeneic bone marrow transplantation. Br J Haematol 1999; 104:569-573.
4. Riddell S, Appelbaum FR, Buckner CD, Stewart P, Clift R, Sanders J, et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J Clin Oncol 1988; 6:576-582.
5. Slevin ML, Johnston A, Woolland RC, Piall EM, Lister TA, Turner P. Relationship between protein binding and extravascular drug concentration of a water-soluble drug, cytosine arabinoside. J R Soc Med 1983; 76:365-368.
6. Kreis W,Woodcock TM, Meyers MB, Carlevarini LA, Krakoff IH. Physiologic disposition of cytosine arabinoside and its derivatives in man. Cancer Treat Rep 1977; 61:723-726.
7. Bury RW, Keary PJ. Determination of cytosine arabinoside in human plasma by high-pressure liquid chromatography. J Chromatogr 1978; 146:350-353.
8. Ho DHW, Frei E. Clinical pharmacology of 1-b-D-arabinofuranosyl cytosine. Clin Pharmacol Ther 1971; 12:944-954.
9. DeAngelis LM, Kreis W, Chan K, Dantis E, Akerman S. Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. Cancer Chemother Pharmacol 1992; 29:173-177.
10. Harris AL, Grahame-Smith DG. Variation in sensitivity of DNA synthesis to Ara-C in acute myeloid leukaemia. Br J Haematol 1980; 45:371-379.